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ABSTRACT 
A sustained-release tablet formulation should ideally have a proper release profile insensitive to moderate changes in tablet hardness that is 
usually encountered in manufacturing. Isoxsuprine hydrochloride is structurally a novel vasodilator. The short biological half-life (5±2 hr) and 
the fast clearance make the drug, a suitable candidate for the development of modified release formulation. A novel oral controlled delivery 
system for isoxsuprine hydrochloride was developed and optimized. Matrix tablets of isoxsuprine hydrochloride were prepared by using 
hydroxypropylmethylcellulose (HPMC K15), Gaur Gum and PVP K 30 as polymer substance to achieve required sustained release profile. The 
matrix tablets were prepared by direct compression method which is now days considered a cost effective and simple method of 
manufacturing. It is considered as an appropriate method for hygroscopic and thermolabile substances. Six formulations of dif ferent polymer 
percentages were formulated (F1-F6). Pre-compression parameters were evaluated. The influence of matrix forming agents and binary 
mixtures of them on isoxsuprine hydrochloride release was investigated. The formulated tablets were characterized by hardness, friability, 
thickness, weight variation and in vitro drug release. The formulated tablets had acceptable physicochemical characters. There was no chemical 
interaction found between the drug and excipients throughout FT-IR and UV study thought of in the present investigation. The quantity of 
isoxsuprine hydrochloride present in the tablets and the release medium were estimated by a simple, rapid and validated UV me thod. The 
dissolution results show that increased amount of polymer resulted in reduced and extended drug release. F4 formulation is the optimum 
formulation due to its better targeting profile in terms of release. First order kinetic profiles were achieved. This formulation may provide an 
alternative for oral controlled delivery of isoxsuprine hydrochloride and be helpful in the future treatment of   peripheral vascular disease.  
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INTRODUCTION 
Isoxsuprine hydrochloride is structurally a novel 
vasodilator1. The short biological half-life (5±2 hr) and the 
fast clearance make the drug, a suitable candidate for the 
development of modified release formulation. Oral 
administration of drugs is generally preferred, especially 
over parenteral administration. Oral products are produced 
in a more cost-effective manner in comparison with 
parenteral products and account for approximately 60% of 
all prescription products worldwide2. Sustained-release oral 
drug products are designed to slowly release the active 
ingredient over an extended time following administration 
and offer significant advantages over conventional orally 
administered products, including reduce side effects, 
increase safety and patient compliance by reducing the 
frequency of dosing and decreased drug plasma-
concentration fluctuations3,4. Matrix formulations of 
hydrophilic and/or hydrophobic polymers have been used to 
control the release of drugs5,6 and can be produced using 
conventional processing equipment. Formulation based on a 
hydrophilic matrix was chosen, since it is known to give 
robust formulae that can be manufactured by standard 
tabletting technology. In addition, it is possible to 
manufacture such formulations without using organic 
solvents; environmental risks associated with such solvents 
cause great concern and they often yield trace residues in 
finished products. To control and modulate drug release 
properties of tablets, retardant polymers including 
hydrophilic polymers such as HPMC and guar gum have been 
utilized in solid dosage forms. For these reterdants, 
hydrophilic polymers control drug release from tablets by 
hydrogelation7,8. HPMC has been employed extensively as 
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hydrophilic matrix former in oral controlled-release dosage 
forms for different drugs. Its popularity can be attributed to 
the polymer’s non-toxic nature, small influence of processing 
variables on drug release, ease of compression and its 
capability to accommodate high levels of drug loading, its 
ability to swell upon jellification once in contact with water9-
11. Thus, an attempt has been made to formulate the 
extended-release matrix tablets of Isoxsuprine 
hydrochloride and tested for controlled delivery of drug 
using matrix polymer. 
MATERIALS AND METHODS  
Materials 
Isoxsuprine hydrochloride was procured from Corel Pharma 
Chem, Ahmedabad, India.  HPMC K15, guar gum and PVP K30 
was obtained from Central Drug House (CDR), Delhi. Lactose 
and Talc was purchased from Loba chem Pvt. Ltd., Mumbai 
(India) and magnesium stearate was purchased from Moly 
Chem. Mumbai (India). All other solvents and reagents were 
purchased from Merck (Germany) and were of analytical 
grade. 
Methods 
Preformulation studies 
Solubility study 
The drug sample was qualitatively tested for its solubility in 
various polar, semi polar and non polar solvents. Solubility of 
the drug was determined by taking about 10 mg of drug 
sample in a test tube containing 2.0 ml of solvent and 
shaking for 10 min at room temperature and observed for its 
solubility. 
FT-IR spectroscopy  
Infra- red spectrum is an important record which gives 
sufficient information about the structure of a compound.  
This technique provides a spectrum containing a large 
number of absorption band from which a wealth of 
information can be derived about the structure of an organic 
compound. The region from 0.8 µ to 2.5 µ is called Near 
Infra-red and that from 15 µ to 200 µ is called Far infra-red 
region. Approx 5 mg of drug was mixed with KBr and 
prepared their pallet. Pallet was analyse using FT-IR 
spectrophotometer (Bruker, USA). 
Determination of λ max of isoxsuprine hydrochloride 
The λmax of Isoxsuprine hydrochloride was determined by 
analyzing the drug solution in double beam ultraviolet 
spectrophotometer.  Accurately weighed 10 mg of drug was 
dissolved in 10 ml of 0.1 N HCL solutions in 10 ml of 
volumetric flask. The resulted solution was 1000µg/ml of 
strength and from this solution 1 ml solution was pipette out 
and transfer into 10 ml capacity of volumetric flask and 
volume was made upto 10 ml with 0.1 N HCL solutions. This 
solution was scan at wavelength 400-200 nm on UV 
spectrophotometer (Labindia-3000 Plus). The higher 
absorption peak was obtained at 277 nm which was the 
λmax of drug. 
Compatibility studies of drug and excipients 
In the compatibility testing program, blends of drug and 
excipients are prepared by triturating the drug with 
Individual excipients. Mixture of Isoxsuprine hydrochloride 
(50 mg) and excipients (50 mg) was prepared and 
transferred to inert glass vials. Vials were covered with 
rubber closures followed by the aluminum seal caps. The 
vials were stored at 4˚C (refrigerator) as control and at 
40˚C/75%RH for accelerated temperature condition for 4 
weeks. The visual observations (color, flow, & sticking) were 
recorded. Sample were analyze for any interaction by using 
UV spectrophotometer (Labindia-3000 Plus). 
Method for preparation of sustained release isoxsuprine 
hydrochloride matrix tablets  
Sustain release matrix tablets were prepared by direct 
compression method. Accurately weighed quantity of all the 
excipients and drug such as Isoxsuprine hydrochloride, 
HPMC K15, gaur gum, PVP K30, magnesium stearate and talc 
were mixed and passed from 16 no sieve. Then blend was 
feed in hopper and tablets were prepared by direct 
compression using multi station automatic rotatory 
punching machine. The tablets were prepared using the 
punch of 8 mm diameter using the rotary tablet processing 
machine. The composition of formulation was given in table 
1.
 
Table 1 Composition of SR matrix tablet of isoxsuprine hydrochloride 
S. No. Ingredients F1 F2 F3 F4 F5 F6 
1 
Isoxsuprine 
hydrochloride 
10 10 10 10 10 
10 
2 HPMC K15 70 80 90 - - - 
3 Gaur Gum - - - 70 80 90 
4 PVP K 30 5 5 5 5 5 5 
5 Lactose  150 140 130 150 140 130 
6 Talc  10 10 10 10 10 10 
7 Magnesium Stearate 5 5 5 5 5 5 
Total Weight 250 250 250 250 250 250 
 
 
Evaluation of isoxsuprine hydrochloride SR matrix 
tablets 
Pre-compression Parameters 
Angle of repose 
The angle of repose of blends was determined by the funnel 
method. The accurately weighed blend was taken in the 
funnel. The height of the funnel was adjusted in such a way 
that the tip of the funnel just touched the apex of the heap of 
the blend. The blend was allowed to flow from the funnel on 
the surface. The diameter and height of the heap formed 
from the blend were measured. The angle of repose was 
calculated using the following formula12. 
Tan Ѳ= h/r 
Where, “h” is the height of the heap and “r” is the radius of 
the heap of granules. 
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Bulk density (BD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced in to a measuring cylinder. The volume occupied 
by the powder was measured which gave bulk volume. The 
BD of powder blends was determined using the following 
formula13. 
               
                     
                      
 
Tapped bulk density (TBD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced into a measuring cylinder. The measuring 
cylinder was tapped until no further change in volume was 
noted which gave the tapped volume. The TBD of powder 
blends was determined using the following formula14. 
      
                     
                             
 
Carr’s compressibility index 
The Carr’s compressibility index was calculated from bulk 
density (BD) and tapped density of the blend. A quantity of 2 
g of blend from each formulation, filled into a 10 ml of 
measuring cylinder. Initial bulk volume was measured, and 
cylinder was allowed to tap from the height of 2.5 cm. The 
tapped frequency was 25 ± 2/min to measure the tapped 
volume of the blend. The BD and tapped density were 
calculated by using the bulk volume and tapped volume. 
Carr’s compressibility index was calculated using the 
following formula15,16. 
                                   
                           
              
     
Hausner’s ratio 
It is the measurement of frictional resistance of the drug. The 
ideal range should be 1.2-1.5, it was determined by the ratio 
of tapped density and bulk density. 
HR = Tapped Density/ Bulk Density 
Post-compression parameters 
Shape of tablet 
Directly compressed tablets were examined under the 
magnified lens for the shape of the tablet. 
Thickness 
Twenty tablets from the representative sample were 
randomly taken and individual tablet thickness was 
measured by using digital vernier caliper17. 
Hardness 
Tablet hardness was measured by using Monsanto hardness 
tester. From each batch six tablets were measured for the 
hardness and average of six values was noted along with 
standard deviations. 
Friability test 
From each batch, ten tablets were accurately weighed and 
placed in the friability test apparatus (Roche friabilator). 
Apparatus was operated at 25 rpm for 4 minutes and tablets 
were observed while rotating. The tablets were then taken 
after 100 rotations, de dusted and reweighed. The friability 
was calculated as the percentage weight loss. 
% friability was calculated as follows 
% Friability = (W1 – W2) x 100/W1 
Where W1 = Initial weight of the 10 tablets, W2 = Final 
weight of the 10 tablets after testing. 
Friability values below 0.5-1% are generally acceptable18. 
Weight variation test 
To study weight variation individual weights (WI) of 20 
tablets from each formulation were noted using electronic 
balance. Their average weight (WA) was calculated. Percent 
weight variation was calculated as follows. Average weights 
of the tablets along with standard deviation values were 
calculated. 
Drug content  
Tablets were weighed and then powdered by pestle in a 
mortar. 100 mg of powdered sample was taken in a beaker 
containing 20 ml of 0.1 N HCL to dissolve it.  The content of 
the beaker was sonicated for 10 min to extract and dissolve 
out the drug from excipient particles. The solution was 
centrifuged at 3000rpm for 10 min and the supernatant was 
analyzed after suitable dilution at 277 nm using UV 
spectrophotometer (Labindia-3000 Plus). The mean percent 
drug content was calculated as an average of three 
determinations. 
In-vitro drug release study 
In-vitro dissolution studies of prepared tablets were carried 
out using USP Paddle type dissolution test apparatus.  To 
determine the dissolution, 900 ml of 0.1N HCL was taken as 
dissolution media and filled in vessel and temperature was 
maintained at 37±0.5°C. Tablet was droped in vessel and 
rotates the paddle at speed of 50 RPM. The temperature of 
the medium was maintained at 37±0.5°C in whole the 
process. Sample (2 ml) was withdrawn at suitable time 
interval (30, 1, 2, 4, 6, 8, 10 and 12 hrs.) and filtered with pre 
weighted whatman filter paper. The samples were analyzed 
using UV spectrophotometer at λmax 277 nm. Equal amount 
of fresh dissolution medium was replaced after each 
withdrawal.  
Kinetic analysis of dissolution data 
To analyze the in vitro release data various kinetic models 
were used to describe the release kinetics. The zero order 
rate Eq. (1) describes the systems where the drug release 
rate is independent of its concentration. The first order Eq. 
(2) describes the release from system where release rate is 
concentration dependent. Higuchi (1963) described the 
release of drugs from insoluble matrix as a square root of 
time dependent process based on Fickian diffusion Eq. (3). 
The Hixson-Crowell cube root law Eq. (4) describes the 
release from systems where there is a change in surface area 
and diameter of particles or tablets. 
C = K0 t      (1) 
Where, K0 is zero-order rate constant expressed in units of 
concentration/time and t is the time. 
LogC = LogC0 - K1 t / 2.303   (2) 
Where, C0 is the initial concentration of drug and K1 is first 
order constant. 
Q = KHt1/2    (3) 
Where, KH is the constant reflecting the design variables of 
the system. 
Q01/3 – Qt1/3 = KHC t  (4) 
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Where, Qt is the amount of drug remained in time t, Q0 is the 
initial amount of the drug in tablet and KHC is the rate 
constant for Hixson-Crowell rate equation. 
The following plots were made using the in-vitro drug 
release data 
Cumulative % drug release vs. time (Zero order kinetic 
model); Log cumulative of % drug remaining vs. time (First 
order kinetic model); Cumulative % drug release vs. square 
root of time 
(Higuchi model) and cube root of initial concentration minus 
the cube root of percentage of drug remaining in the matrix 
vs. time (Hixson-Crowell cube root law) 18. 
RESULTS AND DISCUSSION 
Solubility of isoxsuprine hydrochloride was freely soluble in 
chloroform, ethanol and methanol, soluble in Phosphate 
Buffer pH 7.4 and in soluble in water. The melting point and 
pH of isoxsuprine hydrochloride was 202-203ºC and 
4.12±0.01 respectively. Moisture content of isoxsuprine 
hydrochloride was found to be 0.06396 mg.  λ max of 
isoxsuprine hydrochloride was found to be 277 nm by using 
UV spectrophotometer (Labindia-3000 Plus) in linearity 
range 5-25 µg/ml Fig.1. Identification of isoxsuprine 
hydrochloride was done by FTIR spectroscopy with respect 
to marker compound. It was identified from the result of IR 
spectrum as per specification Fig.2. UV study was performed 
using spectrophotometer (Labindia-3000 Plus) instruments 
to determine the drug excipients compatibility study Fig 3 
(A, B). 
 
Fig.1 Calibration curve of isoxsuprine hydrochloride at 
277 nm 
 
Fig. 2 FT-IR Spectrum of Pure Drug (isoxsuprine 
hydrochloride) 
 
(A) 
 
(B) 
Fig. 3 UV spectra of isoxsuprine hydrochloride (A) 
isoxsuprine hydrochloride and Excipients (B) 
Tablet powder blend was subjected to various pre-
compression parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density of all the formulations was found to be in 
the range of 0.34±0.02 to 0.37±0.06 (gm/ml) showing that 
the powder has good flow properties. The tapped density of 
all the formulations was found to be in the range of 
0.46±0.03 to 0.48±0.10showing the powder has good flow 
properties. The compressibility index of all the formulations 
was found to be ranging between 21.74±0.21to 29.17±0.14 
which show that the powder has good flow properties. All 
the formulations have shown the Hauser’s ratio ranging 
between 0.10±0.06 to 0.14±0.05 indicating the powder has 
good flow properties. 
The results of post-compression parameters such as the 
uniformity of weight, hardness, thickness, friability and 
disintegration time of the tablets are given in Table 3. All the 
tablets of different batches complied with the official 
requirements of uniformity of weight. The hardness of the 
tablets ranged from 3.9 to 4.3 kg/cm2 and the friability 
values were less than 0.5% indicating that the matrix tablets 
were compact and hard. The thickness of the tablets ranged 
from 2.23 to 2.56 mm. All the formulations satisfied the 
content of the drug as they contained 95 to 98% of 
Isoxsuprine hydrochloride and good uniformity in drug 
content was observed. Thus all the physical attributes of the 
prepared tablets were found be practically within control. 
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Table 2: Result of Pre-compression characterization of powder blend for core tablet formulation 
F. Code 
Bulk 
Density 
Tapped 
Density 
Carr’s Index 
Hausner’s 
Ratio 
Angle of 
Repose 
F1 0.35±0.05 0.47±0.08 25.53±0.12 0.12±0.08 30.25±0.22 
F2 0.36±0.03 0.48±0.09 25.00±0.09 0.12±0.04 32.25±0.12 
F3 0.34±0.02 0.48±0.10 29.17±0.14 0.14±0.05 30.12±0.32 
F4 0.35±0.05 0.46±0.08 23.91±0.16 0.11±0.07 30.45±0.12 
F5 0.36±0.04 0.46±0.03 21.74±0.21 0.10±0.06 32.25±0.32 
F6 0.37±0.06 0.48±0.04 22.92±0.19 0.11±0.09 31.45±0.12 
 
Table 3 Post-compression characterization of core tablet formulation 
F. Code 
Weight 
Variation 
(mg) 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
Friability 
(%) 
Drug 
Content 
(%) 
F1 254±5 2.35 3.9 0.15 98.56 
F2 251±8 2.32 4.1 0.16 95.56 
F3 258±6 2.23 3.9 0.10 96.65 
F4 256±8 2.36 4.2 0.17 98.98 
F5 256±7 2.35 4.1 0.18 98.56 
F6 249±5 2.56 4.3 0.19 98.23 
All value are mean ± SD, n=3 
The tablets were evaluated for in vitro dissolution studies in 
simulated gastric fluid pH 1.2. It was observed that tablets 
were remained intact in upper part of the GIT i.e simulated 
gastric fluid pH for 12 hrs. The results of the optimized 
formulation F3 showed maximum drug release i.e. 
96.65±0.21 % at the end of 12 hrs. The results of release 
studies of formulations F1-F6 was shown in Table 4. The in 
vitro drug release data of the optimized formulation F3 was 
subjected to goodness of fit test by linear regression analysis 
according to zero order, first order kinetic equation, 
Higuchi’s and Korsmeyer’s models in order to determine the 
mechanism of drug release. When the regression coefficient 
values of were compared, it was observed that ‘r’ values of 
first order was maximum i.e. 0.988 hence indicating drug 
release from formulations was found to follow first order 
release kinetics Table 5. 
  
Table 4 In-vitro drug release data for all formulation 
Dissolution Media Time (Hr) 
Cumulative Drug Release (%) 
F1 F2 F3 F4 F5 F6 
Simulated Gastric Fluid 
(pH 1.2) 
0.5 25.65±0.21 22.25±0.12 20.12±0.09 35.65±0.32 32.25±0.12 29.98±0.21 
  1 35.65±0.25 33.32±0.45 30.12±0.21 40.15±0.21 35.65±0.25 34.65±0.12 
  2 46.65±0.32 42.12±0.25 40.12±0.45 49.98±0.25 45.65±0.32 43.12±0.25 
  4 68.98±0.45 65.65±0.32 62.48±0.23 60.45±0.26 59.98±0.14 55.45±.32 
  6 88.98±0.32 85.45±0.14 83.12±0.25 75.36±0.21 74.65±0.12 71.12±0.14 
  8 96.65±0.15 94.63±0.25 92.48±0.65 88.98±0.24 85.65±0.15 80.25±0.25 
 10  97.98±0.12 94.65±0.14 96.65±0.15 98.78±0.19 96.65±0.26 
 12   96.65±0.21    
 
Table 5 Regression analysis data  
Batch 
Zero Order First Order 
R² R² 
F3 0.900 0.988 
 
CONCLUSION 
Direct compression methods can be used alternatively for 
wet granulation, because it is an easier, simplified and 
economical method of manufacturing of tablets. A number of 
research articles are available which are evident that the 
direct compression is a preferred method of tableting. 
Matrix tablet is one of the most convenient approaches for 
the preparation of the sustained release dosage forms. In 
actual practice direct compression of drug, retardant 
material, and additives is done to form a tablet in which drug 
particles are embedded in the matrix core of the retardant. It 
is concluded that modified release tablets of isoxsuprine HCl 
could be prepared using a HPMC K-15 and Gaur gum by 
direct compression method.  The dissolution profile of the 
optimized formulation follows the first order release 
kinetics. The findings of this investigation can be extended to 
industry to cut down the cost of formulation. The sustained 
release matrix tablets of isoxsuprine HCl formulation system 
includes the drug delivery system that achieves slow and 
extended release of the drug over an extended period of 
time.
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